Not sure if I have missed it, but in the quarterly announcement the following was stated
”For our cardiovascular product Revascor®, we had a very productive meeting with the FDA this month which included discussion of a unifying mechanism of action across the continuum of heart failure with inflammation in adults, and potential approval pathways in these patients. The FDA will provide written minutes from the meeting in March.
Should we expect an announcement from MSB or have these already been published somewhere already?
banter and General Discussion, page-9454
-
- There are more pages in this discussion • 1,043 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
91.3¢ |
Change
0.008(0.83%) |
Mkt cap ! $1.050B | |||
| Open | High | Low | Value | Volume |
| 93.0¢ | 93.5¢ | 91.0¢ | $1.913M | 2.066M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 26 | 164108 | 91.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 91.5¢ | 53358 | 16 |
View Market Depth
| Last trade - 10.58am 07/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |